DiaMedica Therapeutics Inc. (DMAC) PT Lowered to $14 at Lake Street Capital Markets

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to DiaMedica Therapeutics Inc. (DMAC) PT Lowered to $14 at Lake Street Capital Markets

DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results

March 14, 2022 4:45 PM EDT

Conference Call and Webcast March 15 at 8:00 am Eastern Time / 7:00 am Central Time

Currently Dosing Patients in Pivotal Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial Team Expanded with Addition of Chief Medical Officer and Chief Commercial Officer Strong Balance Sheet with $45M Cash, Runway Into 2024

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial... More